Interní Med. 2010; 12(7-8): 357-360

Mineral and bone disorder in chronic kidney disease (MBD-CKD)

MUDr.Kamil ®amboch1, MUDr.Jana Zahálková, Ph.D.1,2, MUDr.Zdenka Kosatíková1
1 III. interní klinika FN a LF UP, Olomouc
2 Středomoravská nemocniční, a. s., člen skupiny Agel, Nemocnice ©ternberk

Mineral and bone disorder in chronic kidney disease (MBD-CKD) is defined by the presence of one or more of the three components: renal

osteopathy, abnormal metabolism of calcium, phosphorus and parathyroid hormone, and vascular calcifications. Hyperphosphataemia,

elevated parathormon levels and calcitriol deficiency are independently associated with increased mortality. The most common type in

renal osteopathy is the mixed bone disease, occurring in up to 80 % of dialysis patiens, which is a combination of fibrous osteodystrophy

and osteomalacia. Vascular component of CKD-MBD is significant for its close relationship to cardiovascular complications.

Keywords: renal osteopathy, vascular calcifications, hyperphosphataemia, mineral and bone disorder in chronic kidney disease

Published: August 12, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
®amboch K, Zahálková J, Kosatíková Z. Mineral and bone disorder in chronic kidney disease (MBD-CKD). Interní Med. 2010;12(7-8):357-360.
Download citation

References

  1. Moe S, Druke T, Cunningham J, et al. Definition, evaluation and classification of renal osteodystrophy: a positron statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1946-1963. Go to original source... Go to PubMed...
  2. Sulková Dusilová S, a kol. Renální osteopatie. Edice Farmakoterapie pro praxi, svazek 22 Maxdorf 2007: 46-48, 53, 57, 124.
  3. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in chronic kidney disease. Am J Kidney 2003; 42: 10-154.
  4. Sobotová D, Zharfbin A, Neobálková M, et al. Minerálově kostní porucha při chronickém onemocnění ledvin. Vnitř Lék 2007; 53: 841-851. Go to PubMed...
  5. Cannata Andia JB. Pathogenesis, prevention and management for low bone turnover. Nephrol Dial Transplant 2006; 15: 15-17. Go to original source... Go to PubMed...
  6. Dusilová Sulková S, Kalousová M. Některé poznatky o poruąe fosfokalciového metabolismu při selhání ledvin. Postgraduální medicína 2006; 8: 120-126.
  7. Hruska KA, Matjes S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-157. Go to original source... Go to PubMed...
  8. Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int Suppl 2005; 15: 4-8. Go to original source... Go to PubMed...
  9. Coen G. Adynamic bone disease. J Nephrol 2005; 18: 110-126.
  10. Abedin M, Fintit Y, Demer L. Vascular Calcification: Mechanisms and Clinical Ramifications. Arterioscler Tromb Vasc Biol 2004; 24: 1161-1170. Go to original source... Go to PubMed...
  11. Zahálková J. Cévní postiľení při minerálové a kostní nemoci u chronického onemocnění ledvin. Osteologický bulletin 2008; 13(4): 166-171.
  12. Block GA, Maggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patiens. Kidney Int 2007; 71: 438-441. Go to original source... Go to PubMed...
  13. Braun J. Extraosseous Calcification in patiens with chronic renal failure - no espace. Nephrol Dial Transplant 2005; 20: 2054-2059. Go to original source... Go to PubMed...
  14. Ketteler M, Giachelli C. Novel insights into vascular calcification. Kidney Int 2006; 70: 54-62. Go to original source... Go to PubMed...
  15. London GM. Cardiovascular calcification in uremic patiens: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14: S305-309. Go to original source... Go to PubMed...
  16. Schoppet M, Shanahn CM. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure. Kidney Int 2008; 73: 989-991. Go to original source... Go to PubMed...
  17. Dusilová Sulková S. Cinacalceti hydrochloridum. Remedia 2005; 15: 235-245.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.